Title of Invention

"PROCESS FOR THE PREPARATION OF 1,2-DICHLOROETHANE FREE CRYSTALS OF ZONISAMIDE AND THE HIGHLY PURE CRYSTALS OF ZONISAMIDE"

Abstract A process for the preparation of crystals of zonisamide containing residual 1,2-dichloroethane of not more than 5 ppm, by adding an aqueous C2-4 alcohol to crystals of zonisamide containing residual 1,2-dichloroethane of more than 5 ppm, removing the 1,2-dichloroethane by azeotropic distillation, followed by collecting the precipitated crystals from the residual mixture, and the highly pure crystals of zonisamide containing residual 1,2-dichloroethane of not more than 5 ppm, which is useful as an antiepileptic agent.
Full Text DESCRIPTION
TECHNICAL FIELD
The present invention relates to a process for the
preparation of highly pure crystals of zonisamide (chemical
name: 1,2-benzisoxazole-3-methanesulfonamide) , i.e., 1,2-
dichloroethane-free crystals of zonisamide, which is useful
as an antiepileptic agent. More particularly, the present
invention relates to a process for efficiently preparing
crystals of zonisamide containing residual 1,2-dichloro-
ethane of not more than 5 ppm, and the 1,2-dichloroethanefree
crystals of zonisamide thus obtained.
BACKGROUND ART
Zonisamide has widely been used as an antiepileptic
agent in many countries such as Japan, the United States.
Zonisamide and processes for the preparation thereof are
disclosed in JP-A-53-77057, USP 4,172,896 and JP-A-54-
163823. In addition, Yakugaku-Zasshi, vol. 116, p. 533-547
(1996) discloses t"hst ?.onisamid° h?is actual"! v been rrorri"ed
using as an intermediate 1,2-benzisoxazole-3-methanesulfonyl
chloride, which is obtained by sulfonation and
decarboxylation of 1,2-benzisoxazol-3-acetic acid. Further,
the solvent for the above sulfonation and decarboxylation
is dichloromethane in the process disclosed in Yakugaku-
Zasshi, vol. 116, p. 533-547 (1996), and 1,2-dichloroethane
in the process disclosed in JP-A-53-77057.
The solvent used in the preparation of a drug
substance cannot completely be removed by practical
manufacturing techniques, which are in actuality employed
in the production. Therefore, in the preparation of drug
substance wherein plural steps are serially carried out
till the final step, each solvent used in each step may
remain in a residual amount in the drug substance. Further,
residual solvents in the drug substance usually cannot be
useful for the therapeutic benefits of the drug substance,
and contrarily, there may be caused a problem of safety of
a patient according to the kinds of residual solvents and a
concentration thereof. In terms of improving and
increasing the safety of drugs, "IMPURITIES: GUIDELINE FOR •
RESIDUAL SOLVENTS", ICH Harmonized Tripartite Guideline, 17
July 1997 was made in INTERNATIONAL CONFERENCE ON
HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF
PHARMACEUTICALS FOR HUMAN USE (ICH).
Since a solvent may play an important role in
increasing the yield rate or in determination of physical
properties of drug substance such as crystal form, purity,
solubility, etc., even if such a solvent is known to be
toxic, there may be many cases that the use thereof in the
preparation of drug substance cannot be avoided in terms of
risk-benefits. In such cases, this guideline decrees that
a concentration of a residual solvent in the drug substance
should be not more than a limit which is toxicologically
acceptable.
A solvent for the preparation of the intermediate for
zonisamide, 1,2-benzisoxazole-3-methanesulfonyl chloride,
is 1,2-dichloroethane rather than dichloromethane. That is
because, during the decarboxylation, which is carried out
after the sulfonation of 1,2-benzisoxazole-3-acetic acid,
the reaction mixture requires to be heated at about 60°C,
which is higher than the boiling point of dichloromethane.
In addition, 1,2-dichloroethane can be used as well in the
step of preparation of zonisamide by reacting 1,2-benzisoxazole-
3-methanesulfonyl chloride with ammonia. However,
when zonisamide is prepared using 1,2-dichloroethane, the
residual concentration thereof should be not more than 5
ppm as defined in the above-mentioned guideline
"IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS". This
guideline is not applied to the drugs, which are already on
market, but it is very important to prepare a drug
substance complying with this guideline in terms of safety
of drugs.
The removal of a residual solvent is usually carried
out by drying. However, it is very difficult to completely
remove an occluded solvent by a drying method being
actually employed in the' production. USP 4,533,746
discloses a method of removing the solvent by distillation
in purification of bisphenols, wherein the solvent occluded
in bisphenols is released and removed from bisphenol melted
in water. This method utilizes the characteristic of
bisphenol, which melts in water by heating, and thereby the
occluded solvent is released. On the other hand,
zonisamide cannot melt even by heating in water, and hence,
this method cannot be applied for removal of the solvent
occluded in crystals of zonisamide.
DISCLOSURE OF INVENTION
The present inventors have intensively studied a
process for the preparation of crystals of zonisamide
having a high safety and complying with the above-mentioned
guideline, and have found that the desired crystals of
zonisamide containing residual 1,2-dichloroethane of not
more than 5 ppm can easily be obtained even from crystals
of zonisamide containing 1, 2-dichloroethane in a high
concentration, by using an aqueous C2_4 alcohol, i.e., by
the steps of adding an aqueous C2_4 alcohol to said crystals
and distilling the resulting mixture, followed by
crystallization, without equipping any additional apparatus
to existing ones, or without repetition of recrystallization,
and further there are no affects on the yield
thereof, and finally the present inventors have
accomplished the present invention.
The present invention provides a process for the
preparation of a highly pure crystals of zonisamide,
particularly crystals of zonisamide containing residual
1,2-dichloroethane of not more than 5 ppm. The present
invention also provides the highly pure crystals of
zonisamide, i.e., 1,2-dichloroethane-free crystals of
zonisamide, particularly crystals of zonisamide containing
residual 1,2-dichloroethane of not more than 5 ppm.
The present invention includes the following
embodiments:
1. A process for the preparation of crystals of
zonisamide containing residual 1,2-dichloroethane of not
more than 5 ppm, which comprises adding an aqueous C2.4
alcohol to crystals of zonisamide containing residual 1,2-
dichloroethane of more than 5 ppm, usually more than 5 ppm
to 200000 ppm, removing said 1,2-dichloroethane by
azeotropic distillation to obtain a residual mixture,
followed by collecting precipitated crystals of zonisamide
containing not more than 5 ppm of 1,2-dichloroethane from
the residual mixture.
2. A process for the preparation of crystals of
zonisamide containing residual 1,2-dichloroethane of not
more than 5 ppm, which comprises the following steps (a),
(b), (c) and (d) :
(a) dissolving crystals of zonisamide containing
residual 1,2-dichloroethane of more than 5 ppm in an
aqueous C2.4 alcohol, and subjecting the resultant mixture
to azeotropic distillation;
(b) stopping the distillation after the azeotropic
distillation of said 1,2-dichloroethane is completed to
obtain a residual mixture;
(c) cooling the residual mixture to precipitate
crystals of zonisamide containing not more than 5 ppm of
1,2-dichloroethane; and
(d) collecting the precipitated crystals of
zonisamide by filtration and drying thereof.
3. A process for the preparation of crystals of
zonisamide containing residual 1,2-dichloroethane of not
more than 5 ppm, which comprises the above steps (a) and
(b), and the following steps (cl) and (dl):
(cl) adding the same C2.4 alcohol as used in the step
(a) and/or water to the residual mixture obtained in the
step (b), dissolving the residual mixture with heating, and
cooling thereof to precipitate crystals of zonisamide
containing not more than 5 ppm of 1,2-dichloroethane; and
(dl) collecting the precipitated crystals of
zonisamide by filtration and drying thereof.
4. The process according to any one of the above 1
to 3, wherein the aqueous C2.4 alcohol is an aqueous
isopropanol.
5. . The process according to any one of the above 1
to 3, wherein the aqueous C2_4 alcohol is isopropanol
containing water in an amount of 35 to 65 % by volume.
6. The process according to .the above 2 or 3,
wherein the temperature at which the distillation is
stopped is in the range of from 78°C to 100°C.
7. Zonisamide crystals containing not more than 5
ppm of residual 1,2-dichloroethane.
8. Zonisamide crystals containing less than 1 ppm of
residual 1,2-dichloroethane.
9. Zonisamide crystals having a residual 1,2-
dichloroethane content, said residual content being not
more than 5 ppm.
10. Zonisamide crystals prepared by the process of
any one of the above 1 to 6.
The materials used in the present invention and the
conditions and steps in the process of the present
invention are explained in more detail below.
The "crystals of zonisamide containing residual 1,2-
dichloroethane of more than 5 ppm" (hereinafter,
occasionally referred to as "starting crystals of
zonisamide") mean crystals of zonisamide containing
residual 1,2-dichloroethane in the range of more than 5 ppm
to 200000 ppm, although the higher limit of the
concentration of said 1,2-dichloroethane is not necessarily
specified. In general, "crystals of zonisamide containing
residual 1,2-dichloroethane of more than 5 ppm" are
crystals of zonisamide containing residual 1,2-dichloroethane
in the range of 8 ppm to 150000 ppm.
The "aqueous C2_4 alcohol" means a mixture of water and
a C2.4 alcohol, and the "C2_ ethanol, propanol, isopropanol, and 2-butanol. The
"aqueous C2.4 alcohol" is preferably aqueous ethanol,
aqueous propanol, or aqueous isopropanol, among them
aqueous isopropanol is most preferable.
The step of removing 1,2-dichloroethane by azeotropic
distillation is usually carried out subsequently to the
step of dissolving the starting crystals of zonisamide in
an aqueous C2H alcohol. The temperature for dissolving the
starting crystals of zonisamide is not necessarily
specified, but it is usually in the range of from 30°C to a
boiling point of the C2.4 alcohol to be used.
The starting crystals of zonisamide are mixed with an
aqueous C,.4 alcohol in an amount of 5 to 15 parts by volume
per 1 part by weight of the starting crystals of zonisamide.
In other words, 1 g of dry weight of zonisamide is mixed
with 5 to 15 ml of an aqueous C2.4 alcohol. The starting
crystals of zonisamide are preferably mixed with an aqueous
C2_4 alcohol in an amount of 5.2 to 10.4 parts by volume per
1 part by weight of the starting crystals of zonisamide.
Preferable aqueous C2_4 alcohol is usually a C2_4
alcohol containing water in 35 to 65 % by volume, and more
preferable one is a C2_4 alcohol containing water in 40 to
60 % by volume, and further preferable one is a C2_4 alcohol
containing water in 45 to 55 % by volume. In the present
specification, for example, the 55 % by volume aqueous C2H
alcohol means a mixture of water in 55 parts by volume and
a C2_4 alcohol in 45 parts by volume.
The distillation may be carried out either under
atmospheric pressure or under reduced pressure, but
preferably is carried out under atmospheric pressure. The
temperature at which the distillation is started is usually
an azeotropic point of 1,2-dichloroethane-an C2_4 alcoholwater.
For example, the azeotropic point of 1,2-dichloroethane-
ethanol-water is 66.7°C, and the azeotropic point of
1,2-dichloroethane-isopropanol-water is 69.7°C, but these
azeotropic points may vary under the influences of
barometric pressure when the distillation is carried out or
of molar elevation of boiling point, etc. The temperature
at which the distillation is stopped may vary according to
the kinds of the aqueous C2.4 alcohol to be used, and it is
usually in the range of from 78°C to 100°C, preferably in
the range of from 85°C to 100°C, and more preferably in the
range of 90°C to 100°C.
After the distillation is stopped, the residual
mixture is cooled in situ to precipitate crystals of
zonisamide containing residual 1,2-dichloroethane of not
more than 5 ppm. In addition, crystals of zonisamide may
be precipitated in the middle of the distillation procedure.
Therefore, in cases that crystals are precipitated in the
residual mixture after the distillation is stopped, the
same C2.t alcohol as that to be used in the distillation
procedure and/or water are added to the residual mixture
after the distillation is stopped, and the resulting
mixture is heated again to dissolve the crystals, and then
cooled to precipitate crystals of zonisamide containing
residual 1,2-dichloroethane of not more than 5 ppm. For
instance, when an aqueous isopropanol is used in the
distillation procedure, water and/or isopropanol are added
to the residual mixture after the distillation in such an
amount that the ratio of water and isopropanol in the
residual mixture after the distillation becomes in the
range of 35:65 to 65:35, preferably in the range of 40:60
to 60:40, more preferably in the range of 45:55 to 55:45,
and the total volume of water and isopropanol becomes 2 to
20 parts by volume, preferably 8 to 14 parts by volume, per
1 part by weight of the starting crystals (in dry state) of
zonisamide, and the resulting mixture is heated again and
then cooled. This step is preferably carried out together
with the purification using activated carbon.
The crystallized zonisamide is collected by filtration
and dried by a conventional method to give crystals of
zonisamide containing residual 1,2-dichloroethane of not
more than 5 ppm, and in many cases, there are obtained
crystals of zonisamide containing residual 1,2-dichloroethane
of less than detection limit. The crystals of
zonisamide to be collected by filtration are dried at a
temperature of from 60 to 100°C, preferably at a
temperature of from 70 to 90°C, for 8 to 24 hours,
preferably for 12 to 18 hours. Vacuum drying is more
preferable.
The starting crystals of zonisamide to be used in the
present process may be prepared according to the method
disclosed in Reference Example 3 and Example 1 of JP-A-53-
77057, except for the solvent, which is the one used in
Example 1. That is, it is prepared by reacting 1,2-benzisoxazole-
3-methanesulfonyl chloride with ammonia in 1,2-
dichloroethane as a solvent, concentrating the reaction
mixture, adding water to the resulting residue, followed by
collecting the precipitated crystals to give wet crystals
containing zonisamide in an amount of about 85 % by weight.
The wet crystals containing zonisamide in an amount of
about 85 % by weight obtained in the above process are
recrystallized from 50 % aqueous isopropanol in usual
manner, and the resulting crystals are dried under reduced
pressure at a temperature of from 40 to 80°C for 18 hours
to give crystals of zonisamide containing residual 1,2--
dichloroethane in a concentration of from 8 to 14 ppm.
BEST MODE FOR CARRYING OUT THE INVENTION
The present invention is illustrated in more detail by
the following Examples, but the present invention should
not be construed to be limited thereto. The content of
1,2-dichloroethane in crystals of zonisamide was measured
by gas chromatography.
Example 1
To wet crystals (60 g) containing zonisamide in an
amount of about 85 % by weight prepared by using 1, 2--
dichloroethane in the method disclosed in Reference Example
3 and Example 1 of JP-A-53-77057 was added 50 vol % aqueous
isopropanol (500 ml), and 320 ml of the solvent was removed
by evaporation at a temperature of from 76 to 100°C under
stirring. To the residual mixture were added water (10 ml),
isopropanol (200 ml) and activated carbon (8 g), and the
mixture was dissolved with heating. The activated carbon
was separated by filtration, and washed with 50 % aqueous
isopropanol (80 ml). The filtrate and the washing were
combined and cooled. The precipitated crystals were
collected by filtration, washed with water (100 ml), and
dried at 80°C for 16 hours to give crystals of zonisamide
(48.5 g) . The content of 1,2-dichloroethane in the
crystals was less than 1 ppm (less than detection limit).
Examples 2-3
The same procedures as Example 1 were repeated except
that the water content in the aqueous isopropanol and the
amount of the aqueous isopropanol were changed. The
results are shown in Table 1.
Example 4
To the same wet crystals (60 g) containing zonisamide
in an amount of about 85 % by weight as used in Example 1
were added 50 vol % aqueous isopropanol (300 ml), water
(7.5 ml) and I,2-dichloroethane (8.8 g), and 210 ml of the
solvent was removed by evaporation at a temperature of from
79 to 100°C under stirring. The residual mixture was
cooled, and the precipitated crystals were collected by
filtration to give wet crystals of zonisamide (56.7 g).
The content of 1,2-dichloroethane in the wet crystals of
zonisamide was less than 1 ppm (less than detection limit).
The wet crystals were dried at 80°C for 16 hours to give
dried crystals of zonisamide (49.9 g) .
Examp1p 5
To the dried crystals of zonisamide (50.0 g) was added
55 vol % aqueous isopropanol (260 ml), and thereto were
further added 1,2-dichloroethane (7.5 g) and water (7.5 g),
and the mixture was stirred at a stirring velocity of 220
rpm. Then, the mixture was heated until the inner
temperature thereof became 100°C, and 160 ml of the solvent
was removed by evaporation. The residual mixture was
cooled, and thereto were added water (145 ml), isopropanol
(230 ml) and activated carbon (9.1 g), and the mixture was
heated at a temperature of from 80 to 83°C for one hour.
The activated carbon was separated by filtration, and
washed with 50 % aqueous isopropanol (175 ml). The
filtrate and the washing were combined and cooled. After
cooled to about 8°C, the precipitated crystals were
collected by filtration and washed with water (136 ml).
The crystals were dried with air blowing at 100°C for 16
hours to give the dried crystals of zonisamide (47.1 g) .
INDUSTRIAL APPLICABILITY
By conventional methods for recrystallization,
crystals of zonisamide containing residual 1,2-dichloroethane
of not more than 5 ppm could not be obtained from
the starting crystals of zonisamide prepared using 1,2-
dichloroethane. On the contrary, the content of the
residual 1,2-dichloroethane in the crystals of zonisamide
prepared by the Examples of the present process is less
than 1 ppm (less than detection limit), which is far lower
than required 5 ppm. As shown in Example 4, the present
process is effective and applicable even if there is a
large residual amount of 1,2-dichloroethane in the starting
crystals of zonisamide. In addition, as shown in Example 5,
the yield of crystals of zonisamide is not so reduced even
by subjecting them to the present process.
As explained in the above, according to the method of
the present invention, crystals of zonisamide containing
residual 1,2-dichloroethane of not more than 5 ppm can
effectively be obtained from the starting crystals of
zonisamide prepared using 1,2-dichloroethane as the solvent.







We Claim:
1. A process for the preparation of crystals of zonisamide of chemical name 1, 2-
benzisoxazole-3-methanesulfonamide containing residual 1,2 dichloroethane of not more than 5 ppm, which comprises adding an aqueous C2-4 alcohol to crystals of zonisamide containing residual 11,2-dichloroethane of more than 5 ppm, removing said 1,2-dichloroethane by azeotropic distillation to obtain a residual mixture, followed by cooling and collecting the precipitated crystals of zonisamide containing not more than 5 ppm of 1 ,2-dichloroethane from the residual mixture.
2. A process for the preparation of crystals of zonisamide containing residual 1,2-
dichloroethane of not more than 5 ppm as claimed in claiml, which comprises the following steps
(a),(b)(c)axi(d)
(a) dissolving crystals of zonisamide containing residual 1,2 dichloroethane of more
than 5 ppm in an aqueous C2-4 alcohol, and subjecting the resultant mixture to azeotropic
distillation;
(b) stopping the distillation after the azeotropic distillation of said 1 ^-dichloroethane
is completed to obtain a residual mixture;
(c) cooling the residual mixture to precipitate crystals of zonisamide containing not more than 5 ppm of 1,2-dichloroethane; and
(d) collecting the precipitated crystals of zonisamide by filtration and drying thereof.
3. A process for the preparation of crystals of zonisamide containing
residual 1,2-dichloroethane of not more than 5 ppm as claimed in claiml, which
comprises the following steps (a), (b), (cl) and (dl):
(a) dissolving crystals of zonisamide containing residual 1,2-dichloroethane of more than 5 ppm in an aqueous C2-4 alcohol, and subjecting the resultant mixture to azeotropic distillation;
(b) stopping the distillation after the azeotropic distillation of said 1,2-dichloroethane is completed to obtain a residual mixture;
(cl) adding the same C2-4 alcohol as used in the step (a) and/or water to the residual mixture obtained in the step (b), dissolving the residual mixture with heating, and cooling thereof to precipitate crystals of zonisamide containing not more than 5 ppm of 1,2-dichloroethane; and


(dl) collecting the precipitated crystals of zonisamide by filtration and drying thereof.
4. The process as claimed in claim 1, wherein the aqueous C2-4 alcohol is
an aqueous isopropanol.
5. The process as claimed in claim 1, wherein the aqueous C2-4 alcohol is isopropanol containing water in an amount of 35 to 65 % by volume.
6. The process as claimed in claim 2, wherein the temperature at which the distillation is stopped is in the range of from 78°C to 100°C.



Documents:

2905-DELNP-2005-Abstract-(28-03-2008).pdf

2905-delnp-2005-abstract.pdf

2905-DELNP-2005-Claims-(04-12-2008).pdf

2905-DELNP-2005-Claims-(25-11-2008).pdf

2905-DELNP-2005-Claims-(28-03-2008).pdf

2905-delnp-2005-claims.pdf

2905-DELNP-2005-Correspondence-Others-(04-12-2008).pdf

2905-DELNP-2005-Correspondence-Others-(25-11-2008).pdf

2905-DELNP-2005-Correspondence-Others-(28-03-2008).pdf

2905-delnp-2005-correspondence-others.pdf

2905-delnp-2005-description (complete).pdf

2905-DELNP-2005-Form-1-(28-03-2008).pdf

2905-delnp-2005-form-1.pdf

2905-delnp-2005-form-18.pdf

2905-DELNP-2005-Form-2-(28-03-2008).pdf

2905-delnp-2005-form-2.pdf

2905-delnp-2005-form-26.pdf

2905-DELNP-2005-Form-3-(28-03-2008).pdf

2905-delnp-2005-form-3.pdf

2905-delnp-2005-form-5.pdf

2905-delnp-2005-form-6.pdf

2905-delnp-2005-pct-101.pdf

2905-delnp-2005-pct-210.pdf

2905-delnp-2005-pct-304.pdf

2905-delnp-2005-pct-308.pdf


Patent Number 227721
Indian Patent Application Number 2905/DELNP/2005
PG Journal Number 05/2009
Publication Date 30-Jan-2009
Grant Date 19-Jan-2009
Date of Filing 29-Jun-2005
Name of Patentee DAINIPPON SUMITOMO PHARMA CO., LTD.
Applicant Address 6-8, DOSHO-MACHI 2-CHOME, CHUO-KU, OSAKA SHI, OSAKA-FU, JAPAN 541-8524.
Inventors:
# Inventor's Name Inventor's Address
1 UENO, YOSHIKAZU 9-7,NAKANO-CHO 4-CHOME,MIYAKOJIMA-KU,OSAKA-SHI,OSAKA 534-0027 JAPAN.
2 KIMURA,YASUJIRO 1-C18-205,SHINSENRIKITA-MACHI 1-CHOME,TOYONAKA-SHI,OSAKA 560 0081 JAPAN.
PCT International Classification Number C07 D 261/00
PCT International Application Number PCT/JP2003/009530
PCT International Filing date 2003-07-28
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 10/340,601 2003-01-13 U.S.A.